Q&A: BeiGene exec reflects on path that led them to select NJ for a major manufacturing/R&D campus
BeiGene has chosen New Jersey as its next US home, and the plans are massive.
The company will recruit hundreds of people to work at its sixth US location, a 42-acre R&D and manufacturing campus, in Hopewell, NJ, that is set to go up roughly 60 miles away from its other New Jersey office.
The facility will include commercial-stage manufacturing, clinical R&D and the “BeiGene Center for Pharmacovigilance Innovation.” The construction is expected to be completed in mid-2023, and head of technical operations Michael Garvey is set to oversee the operation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.